In short. Describing an exosome injection as research does not make it research. Legitimate research involving people requires a protocol, independent ethics approval, a defined intervention with stated content, consent that sets out what is unknown, a route for reporting harm and oversight by someone other than the person recruiting.
Key points
- Research requires a protocol, ethics approval, a defined intervention and independent oversight.
- The commercial version borrows the language and skips the structure.
- A consent form can only describe risks that are known.
- Without a batch record, harm cannot be traced or investigated.
- With an unapproved injectable, the routes to recourse are thin or absent.
What legitimate research requires
A study involving people needs a protocol written before it begins, review and approval by an independent ethics committee, a defined intervention with a stated content, a written consent process that sets out what is not known, a way to report and treat harm, and oversight by someone who is not the person recruiting participants. Participants are usually told plainly that they may receive no benefit, and payment for an unproven intervention is either absent or disclosed as part of the approved protocol.
What the commercial version looks like
The commercial version borrows the language and skips the structure. The product is described as new, experimental, or still being studied. It is offered as an add-on to a procedure the person has already agreed to, often on the day. There is no protocol, no ethics approval, no independent oversight and no defined intervention, because the product itself is not characterised. The framing explains the absence of approval without anyone having to justify it.
What does the commercial version borrow?
It borrows the authority of research without its protections. Research is a real activity with real safeguards, and when the word is used to describe a paid treatment those safeguards are usually absent. The word is doing a different job: it explains why there is no approval, and it frames an unproven product as a frontier rather than as a gap.
Consent cannot describe unknown risks
A consent form can only describe risks that are known. For a product with no characterisation, no defined dose and no safety data, there is nothing accurate to put in that section. What remains is a document recording agreement to an unspecified intervention, which protects the provider rather than informing the patient.
What happens to the record
An adverse event can only be investigated if someone can identify what was given. Where the product is not recorded by name, batch and source, and where the clinic holds no list of who received which batch, an injury becomes an isolated event with no way to connect it to anything. The people who received the same material cannot be found, and the material cannot be tested. That is the practical cost of the framing: it produces a treatment that leaves no usable trace.
What happens to recourse
If something goes wrong with an approved product, there are routes: a labelled product with a manufacturer, a reporting system, and a complaint process with somewhere to go. With an unapproved injectable given under a research label, those routes are thin or absent. The clinic is the only identifiable party, and the question of what was actually injected may not be answerable even by them.
| Requirement | What legitimate research provides | What the commercial version provides | Consequence |
|---|---|---|---|
| Protocol | Written before the study begins | None described | There is no defined question |
| Ethics approval | Review by an independent committee | None | No independent oversight |
| Defined intervention | A stated content for what is given | A product that is not characterised | Consent cannot describe it |
| Consent | A written process setting out what is unknown | Agreement to an unspecified intervention | The document protects the provider |
| Harm reporting | A route to report and treat harm | Not described | An injury becomes an isolated event |
| Records | Name, batch and source of what was given | No batch record or recipient list | The material cannot be traced or withdrawn |
Which questions separate research from marketing?
- Which ethics committee approved the protocol, and what is the approval reference?
- What exactly is being injected, stated in a way somebody else could check?
- Who is collecting the outcomes, and how would a serious reaction be reported?
A legitimate study has an answer to each of these. A paid treatment described as research usually cannot answer the first at all, and the second is the reason the first is missing.
What should a patient ask before agreeing?
Ask for the protocol and the ethics approval reference before any payment or injection. Ask what the product is, in a form another clinician could check. Ask who is collecting outcomes and how a serious reaction would be reported and treated. Where any of those answers is missing, the word research is not describing a study.
Sources
- American Society of Plastic Surgeons: guidance on informed consent for injectable treatments
- National Institute for Health and Care Excellence: guidance on unlicensed injectable products
- Cochrane Library: systematic reviews on skin rejuvenation interventions
Source links open each organisation's search results for the topic. Document-level confirmation is pending the reviewer's sign-off.
Internal links
Frequently asked questions
What does legitimate research involving patients require?
A protocol written before the study starts, review and approval by an independent ethics committee, a defined intervention with a stated content, a written consent process that tells participants what is not known, a route for reporting and treating harm, and oversight by someone other than the person recruiting. Participants are usually told plainly that they may receive no benefit.
Why can a consent form not describe the risks of an uncharacterised product?
Because consent can only describe risks that are known. For a product with no characterisation, no defined dose and no safety data, there is nothing accurate to write in that section. What remains is a document recording agreement to an unspecified intervention, which protects the provider rather than informing the person receiving it.
What happens to the record when the injected product is not named by batch?
An adverse event can only be investigated if somebody can identify what was given. Where the product is not recorded by name, batch and source, and the clinic holds no list of who received which batch, an injury becomes an isolated event. The material cannot be tested, the other recipients cannot be found, and no stock can be withdrawn.
Risks & Limitations
- No product marketed as an exosome injectable has been through the approval process that would establish what it contains or what it does.
- Birth tissue derived material carries an infection risk when it is injected, and serious infections have been reported after such injections.
- The evidence behind most claims comes from laboratory work, animal models or uncontrolled case series, none of which establishes an effect in people.
- Regulatory status differs by country, and in most markets there is no approval for these products in any injectable use.
- Nothing on this site is a recommendation for or against any treatment, and it does not assess individual cases.
When to Seek Care
- Spreading redness, heat, swelling or discharge at an injection site: have it assessed promptly.
- Fever, or feeling unwell with a painful injected area: seek medical care without waiting.
- Severe or worsening pain, blistering, or skin breakdown where something was injected.
- Any new and persistent symptom after a treatment: have it assessed by a clinician who can examine you.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.